Warfighter Protection and Acute Care
The WPAC PMO protects and sustains the Warfighter from initial service entry, during far-forward deployments, at the point of injury and beyond by developing, delivering, and fielding U.S. FDA-approved preventions, diagnostics, and treatments for infectious diseases and combat wound infections; blood products and blood components; and drugs for battlefield pain management.
These critical capabilities ensure readiness; mitigate and treat infections and illness; reduce morbidity and mortality: and improve recovery.
We focus on enabling the Warfighter's return to the fight and to their families and reducing the logistical burden of carrying and using critical medical materiel on the battlefield.
The WPAC PMO accomplishes its mission by leveraging partnerships with industry, academia, and other governmental agencies to develop medical materiel solutions to satisfy critical requirements generated by the Service Capability Directorates and the user community.
Current WPAC PMO efforts focus on the development of vaccines, drug, diagnostics, and therapeutics for the prevention and treatment of infectious diseases, hemorrhage control and resuscitation solutions for Warfighters and for Military working dogs, as well as drugs for battlefield pain management.
Develop, deliver and field U.S. Food and Drug Administration (FDA)-approved preventions, diagnostics, and treatments for infectious diseases and combat wound infections; blood products and blood components; and drugs for battlefield pain management to protect and sustain the Warfighter during far-forward deployments.
The Warfighter Protection and Acute Care (WPAC) Project Management Office (PMO) serves the medical needs of our U.S. Warfighters. We will advance their health and readiness through continually improving our acquisition strategies and by implementing innovative solutions to accelerate the development and fielding of medical products.
Infectious Disease/Disease Non-Battle Injury Products
Non-Battle Injury Products
The WPAC PMO develops safe and effective therapeutics, vaccines, diagnostics and assays for all relevant threats. We develop vaccines and prophylaxis critical for protecting deployed Service Members against existing and emerging diseases that degrade unit readiness. Deployable diagnostics enable rapid pathogen detection to quickly identify and diagnose infectious diseases in the field enhancing far-forward medical response where evacuation times may be extended. These broad-spectrum capabilities mitigate infections, reduce morbidity, improve recovery and enable the Warfighter's return to the fight.
Battlefield Pain Management
Battlefield pain management focuses on safely and effectively treating pain at, or very close to the point-of-injury. Pain treatments must work quickly, be safe, easy-to-use and lightweight to allow medics to carry sufficient doses for the planned operation. Our new products meet these requirements and add to the pain-treatment options available to care providers.
Blood Products & Components for our Warfighters and Military Working Dogs
Blood products are essential to effective combat casualty care, and early transfusions improve casualty survival rates. Development efforts focus on blood products that can be deployed in austere environments where mobility is required, including cold platelets, freeze-dried plasma and safe whole blood. Our Military Working Dogs (MWD) are critical to saving lives on the battlefield, and they are also at risk for traumatic injuries and hemorrhage. Whole blood is preferred to treat MWDs with severe blood loss, but this is not always available at the point-of-injury. Canine freeze-dried platelets and canine freeze-dried plasma can bridge this gap.